Mizuho Securities analyst Mara Goldstein initiated coverage with a Buy rating on Incyte Corp (INCY) today and set a price target of $95.00. The company’s shares closed last Monday at $73.04.
According to TipRanks.com, Goldstein ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.8% and a 31.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Arcus Biosciences Inc.
Currently, the analyst consensus on Incyte Corp is a Moderate Buy with an average price target of $94.82, representing a 28.2% upside. In a report issued on September 27, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Incyte Corp’s market cap is currently $15.91B and has a P/E ratio of 52.29. The company has a Price to Book ratio of 7.07.
Based on the recent corporate insider activity of 96 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.
